{"disease":{"id":"familial-hypercholesterolemia-heterozygous","name":"Familial hypercholesterolemia - heterozygous","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":18,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inclisiran","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqvio","generic_name":"INCLISIRAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":59,"revenue":"863","mechanism":"Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors."},{"drug_id":"alirocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"niacin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"bempedoic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexletol","generic_name":"BEMPEDOIC ACID","company_name":"Esperion Theraps Inc","drug_phase":"marketed","molecular_target":"ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1)","drug_class":"Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"choline-fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"nicotinic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"lovastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"fluvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04370899","title":"Early Detection of Familial Hypercholesterolemia in Children","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT03501875","title":"Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous","phase":"NA","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04656028","title":"Genetic Testing and Motivational Counseling for FH","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"National Medical Research Center for Therapy and Preventive Medicine","has_results":false},{"nct_id":"NCT07102511","title":"Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT04652726","title":"Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06597019","title":"Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":6},"guidelines":[{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}